TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19289170

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) after temporal lobe surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Left-hemispheric surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Underlying seizure disorder
Number of subjects: 40
Study: 17827861

Group type: EXPERIMENTAL
Intervention: Group smoking cessation intervention based on social cognitive theory
Number of subjects: 225

Group type: COMPARATOR
Intervention: Routine training (control group)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Routine training (control group) after 6 months
Number of subjects: 225
Study: 15088883

Group type: EXPERIMENTAL
Intervention: LDD (20 mg b.i.d.) + AFS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo + AFS
Number of subjects: 24
Study: 11531834

Group type: EXPERIMENTAL
Intervention: Sirolimus 3.0 mg m(‐2) daily + cyclosporin 1.25 mg kg(‐1) daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cyclosporin 5.0 mg kg(‐1) daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cyclosporin 1.25 mg kg(‐1) daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sirolimus alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sirolimus plus reduced‐dose cyclosporin
Number of subjects: 150
Study: 9894177

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 293
Study: 7847746

Group type: EXPERIMENTAL
Intervention: 2 or 4 h sleep regime after 44th‐46th h of sleep deprivation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sleep-deprived controls
Number of subjects: 20
Study: 3395921

Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate (Hylorin)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1.4% polyvinyl alcohol (Refresh)
Number of subjects: 14
Study: 31730369

Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Therapy (ABMT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 37
Study: 30246184

Group type: EXPERIMENTAL
Intervention: Definitive screw-retained, metal-ceramic prosthesis in occlusion within 1 week after placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-occluding provisional acrylic reinforced prosthesis within 24 h of implant placement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Definitive screw-retained, metal-ceramic prosthesis in occlusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-occluding provisional acrylic reinforced prosthesis
Number of subjects: 40
Study: 26620368

Group type: EXPERIMENTAL
Intervention: One course of bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Retroperitoneal lymph node dissection (RPLND)
Number of subjects: 382
Study: 25630699

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 20
Study: 23887468

Group type: EXPERIMENTAL
Intervention: melaxen (melatonin IR)
Number of subjects: 45
Study: 21384320

Group type: EXPERIMENTAL
Intervention: DBE
Number of subjects: 130

Group type: COMPARATOR
Intervention: SBE
Number of subjects: 130
Study: 18199715

Group type: EXPERIMENTAL
Intervention: Blood levels of 18:1n‐9t
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: Total 18:2t
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: Total trans‐fatty acids
Number of subjects: 14916

Group type: COMPARATOR
Intervention: None of the trans fats examined
Number of subjects: 14916
Study: 16814131

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT) with continuous transdermal estradiol patch (36 microg/day) plus cyclic oral medroxyprogesterone acetate (MPA; 2.5 mg/day for 12 days) for 12 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral hormone replacement therapy (HRT) with continuous oral conjugated equine estrogens (CEE; 0.625 mg/day) plus cyclic oral MPA (2.5 mg/day for 12 days) for 12 months
Number of subjects: 38
Study: 12904807

Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11345684

Group type: EXPERIMENTAL
Intervention: Counseling supplemented by physiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Counseling
Number of subjects: 40
Study: 9377880

Group type: EXPERIMENTAL
Intervention: Meropenem (1000 mg every 8 hrs)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Ceftazidime (2000 mg) plus Tobramycin (1 mg/kg every 8 hrs)
Number of subjects: 211
Study: 1539460

Group type: EXPERIMENTAL
Intervention: Vaccination at health centre 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccination at health centre 2
Number of subjects: 0
Study: 2861873

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 31399500

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 157
Study: 27988804

Group type: EXPERIMENTAL
Intervention: Alarm
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Alarm + Desmopressin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Post-intervention assessment
Number of subjects: 82
Study: 25595404

Group type: EXPERIMENTAL
Intervention: Optiflow device (3-mm or 4-mm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard technique)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Optiflow device (4-mm)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Optiflow and control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Optiflow device
Number of subjects: 80
Study: 24099621

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 73
Study: 21792770

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Laparoscopic-assisted surgery (LAS)
Number of subjects: 95
Study: 19154827

Group type: EXPERIMENTAL
Intervention: High-intensity session of 24 repeated right-side slips
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-intensity initial session of a single slip with high-frequency ancillary training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Single-slip exposure without ancillary sessions
Number of subjects: 46
Study: 17283312

Group type: EXPERIMENTAL
Intervention: Levetiracetam (500 mg twice daily)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (200 mg twice daily)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 579

Group type: COMPARATOR
Intervention: Controlled-release carbamazepine
Number of subjects: 579
Study: 12524670

Group type: EXPERIMENTAL
Intervention: Vigorous exercise program (3 half-hour sessions per week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Energy restriction (4,186 to 6,279 kJ.d(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of vigorous exercise and energy restriction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control light exercise program
Number of subjects: 60
Study: 10563033

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment with Nicorette gum
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment with cue exposure
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment with cue exposure and Nicorette gum
Number of subjects: 129
Study: 8899261

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intracervical device in cervical canal (group I)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intracervical device in uterine cavity (group II)
Number of subjects: 298
Study: 1812498

Group type: EXPERIMENTAL
Intervention: maroxepine 2.5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: maroxepine 5.0 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: chlorpromazine 75 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: imipramine 75 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 7107115

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 14
Study: 4025191

Group type: EXPERIMENTAL
Intervention: Beef fat (BF)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Coconut oil (CO)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Safflower oil (SO)
Number of subjects: 19
Study: 29174166

Group type: EXPERIMENTAL
Intervention: Pre-simulation orientation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no pre-simulation orientation)
Number of subjects: 24
Study: 27464018

Group type: EXPERIMENTAL
Intervention: 17 α‐hydroxyprogesterone caproate (17OHP‐C)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 25280414

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) intake as percentage of daily energy (median 5.3%)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA) intake as percentage of daily energy (median 8.2%)
Number of subjects: 118
Study: 22148989

Group type: EXPERIMENTAL
Intervention: 8-week intensive meditation/emotion regulation training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study: 20075928

Group type: EXPERIMENTAL
Intervention: Candesartan therapy for 6 months
Number of subjects: 219
Study: 18503053

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) levels in follicular fluids
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Interleukin (IL-2) levels in follicular fluids
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Interferon (IFN-gamma) levels in follicular fluids
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: IL-12 levels in follicular fluids
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: CCL5 levels in follicular fluids
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: G-CSF levels in follicular fluids
Number of subjects: 132
Study: 15816795

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day titrated to 60 mg/day over 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mirtazapine (continued)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (switched from mirtazapine)
Number of subjects: 30
Study: 12767103

Group type: EXPERIMENTAL
Intervention: ondansetron with dexamethasone
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: doxorubicin
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: cisplatin
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: carboplatin
Number of subjects: 360
Study: 10777431

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8842885

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (6 sessions of thermal training and 6 sessions of electromyographic training over a 6 week period)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No-intervention group
Number of subjects: 150
Study: 1625515

Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg p.o. at 09.00 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6328684

Group type: EXPERIMENTAL
Intervention: Oral ranitidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous ranitidine
Number of subjects: 50
Study: 30182773

Group type: EXPERIMENTAL
Intervention: Motivational interviewing + standard advice (MI + SA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard advice (SA)
Number of subjects: 37
Study: 29415180

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 212
Study: 27572327

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone hexacetonide (TH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 8 mg dexamethasone (DEX)
Number of subjects: 70
Study: 25202955

Group type: EXPERIMENTAL
Intervention: Ambroxol (1,000 mg/d on the day of operation and on the first 3 postoperative days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22704112

Group type: EXPERIMENTAL
Intervention: 200 mg ubiquinol daily for 26 weeks
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 20600480

Group type: EXPERIMENTAL
Intervention: CJ-50300 (conventional dose: 1.0x10(8) plaque-forming units/mL)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: CJ-50300 (low dose: 1.0x10(7) plaque-forming units/mL)
Number of subjects: 123

Group type: COMPARATOR
Intervention: CJ-50300 (conventional dose)
Number of subjects: 123
Study: 19186344

Group type: EXPERIMENTAL
Intervention: Acupuncture needle
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham needle
Number of subjects: 80
Study: 16438875

Group type: EXPERIMENTAL
Intervention: RFA-PEI
Number of subjects: 86

Group type: COMPARATOR
Intervention: RFA
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: RFA-PEI (Group A, diameter <= 3.0 cm)
Number of subjects: 86

Group type: COMPARATOR
Intervention: RFA (Group A, diameter <= 3.0 cm)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: RFA-PEI (Group B, diameter = 3.1-5.0 cm)
Number of subjects: 86

Group type: COMPARATOR
Intervention: RFA (Group B, diameter = 3.1-5.0 cm)
Number of subjects: 86
Study: 11876581

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 487

Group type: COMPARATOR
Intervention: Drug counseling
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Higher psychiatric severity
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Completion of full treatment
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Living situation (with partner vs alone)
Number of subjects: 487
Study: 10655905

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 ng ml‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 ng ml‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (0.0 ng ml‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 ng ml‐1) and (0.6 ng ml‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 9
Study: 8952581

Group type: EXPERIMENTAL
Intervention: High sodium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 0
Study: 1849571

Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation, palatable form, duration up to three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7140435

Group type: EXPERIMENTAL
Intervention: Special 3-week training program including discussions about deafness, communication techniques, and free-play interactions with deaf children.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special 3-week training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 31907056

Group type: EXPERIMENTAL
Intervention: Sang-qi granules (SQG)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sang-qi granules (SQG) and Losartan
Number of subjects: 300
Study: 30511788

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standardised Talking Control (TC)
Number of subjects: 42
Study: 28733314

Group type: EXPERIMENTAL
Intervention: Flutter valve treatment for 30 min/d for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (flutter-sham)
Number of subjects: 17
Study: 25554556

Group type: EXPERIMENTAL
Intervention: Disposable ECG lead wires
Number of subjects: 1611

Group type: COMPARATOR
Intervention: Reusable ECG lead wires
Number of subjects: 1611
Study: 23856626

Group type: EXPERIMENTAL
Intervention: SP-2 (fully channel-by-channel programmable device with automatic noise management and multichannel directional microphone)
Number of subjects: 11

Group type: COMPARATOR
Intervention: SP-1 (multichannel device with omnidirectional microphone)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: SP-2
Number of subjects: 11

Group type: COMPARATOR
Intervention: SP-1 and SP-2
Number of subjects: 11
Study: 22118754

Group type: EXPERIMENTAL
Intervention: 50 g fructose and 33.3 g erythritol
Number of subjects: 37

Group type: COMPARATOR
Intervention: 50 g fructose and 50 g glucose
Number of subjects: 37

Group type: COMPARATOR
Intervention: 50 g fructose alone
Number of subjects: 37
Study: 19233534

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips used twice daily for 30 minutes over a 2-week period
Number of subjects: 148
Study: 16951900

Group type: EXPERIMENTAL
Intervention: Passive training program (manual passive treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Mechanical active passive training
Number of subjects: 18
Study: 15582061

Group type: EXPERIMENTAL
Intervention: Multiple prenatal ultrasound examinations (5 studies between 18 and 38 weeks' gestation)
Number of subjects: 2714

Group type: COMPARATOR
Intervention: Single prenatal ultrasound examination (1 study at 18 weeks' gestation)
Number of subjects: 2714

Group type: EXPERIMENTAL
Intervention: Multiple prenatal ultrasound examinations (5 studies)
Number of subjects: 2714

Group type: COMPARATOR
Intervention: Single prenatal ultrasound examination (1 study)
Number of subjects: 2714
Study: 11745871

Group type: EXPERIMENTAL
Intervention: COMP
Number of subjects: 404

Group type: COMPARATOR
Intervention: D-COMP
Number of subjects: 404
Study: 9292609

Group type: EXPERIMENTAL
Intervention: External nasal dilator (Breathe Right)
Number of subjects: 53
Study: 7678358

Group type: EXPERIMENTAL
Intervention: UW solution
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: UW-mod solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Euro-Collins solution
Number of subjects: 44
Study: 3539363

Group type: EXPERIMENTAL
Intervention: First generation soft-tipped catheters
Number of subjects: 413

Group type: COMPARATOR
Intervention: Conventional catheters
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Second generation soft-tipped catheters
Number of subjects: 413
Study: 31827007

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 15045

Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 15045

Group type: EXPERIMENTAL
Intervention: Low HDL-C level
Number of subjects: 15045

Group type: EXPERIMENTAL
Intervention: At least one component of MetS
Number of subjects: 15045

Group type: EXPERIMENTAL
Intervention: High birth weight
Number of subjects: 15045
Study: 29614991

Group type: EXPERIMENTAL
Intervention: Complete administration of chemotherapy cycles
Number of subjects: 392

Group type: COMPARATOR
Intervention: Incomplete administration of chemotherapy cycles
Number of subjects: 392
Study: 27259099

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIT), tri-weekly running-based program for 16 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (non-exercise follow-up)
Number of subjects: 23
Study: 25827032

Group type: EXPERIMENTAL
Intervention: In SHAPE program (12-month intervention including membership in a public fitness club and weekly meetings with a health promotion coach)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Fitness club membership alone (control group)
Number of subjects: 210
Study: 23374164

Group type: EXPERIMENTAL
Intervention: F-fucoidan (FD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F-fucoidan (FD) + Fucoxanthin (FX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fucoxanthin (FX)
Number of subjects: 0
Study: 19318600

Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) intervention
Number of subjects: 795

Group type: COMPARATOR
Intervention: Mock MTM intervention (control group)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Both groups (opt-in and opt-out)
Number of subjects: 795
Study: 18036090

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 572

Group type: COMPARATOR
Intervention: Control group (community survey)
Number of subjects: 572
Study: 15700733

Group type: EXPERIMENTAL
Intervention: Daily multivitamin supplement containing folic acid, beginning one month before conception and continuing through the first trimester.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: National preventive campaign on parents' behaviour, details not specified.
Number of subjects: 0
Study: 11700852

Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate (TE) 100 mg weekly
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate (TE) 300 mg weekly
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate (TE) 25 mg weekly
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate (TE) 50 mg weekly
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate (TE) 100 mg and 300 mg weekly
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study: 9221556

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of TENS and tactile stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sham stimulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TENS without therapist
Number of subjects: 0
Study: 7636643

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (3 mg of Zn acetate per day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 2539764

Group type: EXPERIMENTAL
Intervention: Nedocromil (2 puffs of 2 mg/puff)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 911607

Group type: EXPERIMENTAL
Intervention: Warning labels showing drugs known to interact
Number of subjects: 140

Group type: COMPARATOR
Intervention: No warning labels (control group)
Number of subjects: 140
Study: 30341969

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing of PPI
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional dosing of PPI
Number of subjects: 60